Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce Cree(University of California, San Francisco), Eliezer Katz, Dean M. Wingerchuk(WinnMed), Jörn Drappa(Integrated BioTherapeutics (United States)), Ari Green(University of California, San Francisco), Jeffrey L. Bennett(University of Colorado Denver), Fred Lublin(Icahn School of Medicine at Mount Sinai), Gary Cutter(Epilepsy Foundation), Brian G. Weinshenker(Mayo Clinic in Arizona), Orhan Aktaş(Heinrich Heine University Düsseldorf), Friedemann Paul(Max Delbrück Center), Hans‐Peter Hartung(The University of Sydney), Kazuo Fujihara(Tohoku University), John N. Ratchford(Johns Hopkins University), Romain Marignier(Hospices Civils de Lyon), Ho Jin Kim(National Cancer Center), Dewei She, Daniel Cimbora, Soraya Madani, Sean J Pittock(Mayo Clinic), Gerard Barron
Cited by 722
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k